Table of Content

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview
Overview
Porter’s Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Threat of Substitutes
Competitiveness in the Industry
Key Concepts of Immunotherapy

Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Rising Cancer Cases Globally
Robust Approval of Immunotherapy Drugs
Rise in Government Funding and Pharmaceutical R&D Spending
Market Restraints
High Cost of Immunotherapy
Loss of Exclusivity and Genericization
Shortage of Oncology Professionals
Market Opportunities
Technological Advances in Immunotherapy
Potential in Cancer Immunotherapy

Chapter 4 Regulatory Landscape
Overview
U.S.
Europe
Japan

Chapter 5 Emerging Technologies
Overview
Artificial Intelligence (AI)
Emergent Biomarkers
Immunotherapy Pipeline
Patent Analysis
Future Prospects

Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global Market for Cancer Immunotherapy, by Therapy Type
Global Market Size and Forecast
Checkpoint Inhibitors
Monoclonal Antibodies
Adoptive Cell Therapies
Cytokine Therapy
Cancer Vaccines
Oncolytic Virus Therapy
Other Immunotherapies
Global Market for Cancer Immunology, by Cancer Type
Global Market Size and Forecast
Melanoma
Leukemia
Lymphoma
Myeloma
Lung Cancer
Breast Cancer
Colorectal Cancer
Other Cancers
Geographic Breakdown
Global Market for Cancer Immunotherapy, by Region
Global Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Competitive Intelligence
Overview
Competitive Landscape
Company Share Analysis

Chapter 8 Sustainability in Cancer Immunotherapy Market: An ESG Perspective
Introduction to ESG
Role of ESG in the Pharma Industry
Sustainability in the Cancer Immunotherapy Market
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
ESG Risk Ratings
Conclusion

Chapter 9 Appendix
Methodology
Abbreviations
Sources
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.



List of Figures


Summary Figure : Global Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 1 : Snapshot of Market Dynamics
Figure 2 : Distribution Share of the Most Frequent Cancer Types in Women*, 2022
Figure 3 : Distribution Share of the Most Frequent Cancer Types in Men*, 2022
Figure 4 : Estimated New Cancer Cases and Deaths in the U.S. in 2024
Figure 5 : National Cancer Institute Research Funding, 2012-2019
Figure 6 : Global Pharmaceutical R&D Spending and Growth, 2020-2026
Figure 7 : Immunotherapy-Related Patents and Publications in the U.S. and China
Figure 8 : Global Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 9 : Global Market Shares of Checkpoint Inhibitors in Cancer Immunotherapy, by Region, 2023
Figure 10 : Global Market Shares of Checkpoint Inhibitors in Cancer Immunotherapy, by Type, 2023
Figure 11 : Global Market Shares of Monoclonal Antibodies in Cancer Immunotherapy, by Region, 2023
Figure 12 : Global Market Shares of Adoptive Cell Therapies in Cancer Immunotherapy, by Region, 2023
Figure 13 : Global Market Shares of Cytokine Therapy in Cancer Immunotherapy, by Region, 2023
Figure 14 : Global Market Shares of Cancer Vaccines in Cancer Immunotherapy, by Region, 2023
Figure 15 : Global Market Shares of Oncolytic Virus Therapy in Cancer Immunotherapy, by Region, 2023
Figure 16 : Global Market Shares of Other Immunotherapies in Cancer Immunotherapy, by Region, 2023
Figure 17 : Global Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 18 : Global Market Shares of Cancer Immunotherapy in Melanoma, by Region, 2023
Figure 19 : Global Market Shares of Cancer Immunotherapy in Leukemia, by Region, 2023
Figure 20 : Global Market Shares of Cancer Immunotherapy in Lymphoma, by Region, 2023
Figure 21 : Global Market Shares of Cancer Immunotherapy in Myeloma, by Region, 2023
Figure 22 : Global Market Shares of Cancer Immunotherapy in Lung Cancer, by Region, 2023
Figure 23 : Global Market Shares of Cancer Immunotherapy in Breast Cancer, by Region, 2023
Figure 24 : Global Market Shares of Cancer Immunotherapy in Colorectal Cancer, by Region, 2023
Figure 25 : Global Market Shares of Cancer Immunotherapy in Other Cancers, by Region, 2023
Figure 26 : Global Market Shares of Cancer Immunotherapy, by Region, 2023
Figure 27 : North American Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 28 : North American Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 29 : North American Market Shares of Cancer Immunotherapy, by Country, 2023
Figure 30 : U.S. Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 31 : U.S. Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 32 : Canadian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 33 : Canadian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 34 : Mexican Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 35 : Mexican Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 36 : European Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 37 : European Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 38 : European Market Shares of Cancer Immunotherapy, by Country, 2023
Figure 39 : German Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 40 : German Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 41 : U.K. Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 42 : U.K. Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 43 : French Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 44 : French Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 45 : Italian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 46 : Italian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 47 : Spanish Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 48 : Spanish Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 49 : Rest of European Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 50 : Rest of European Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 51 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 52 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 53 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Country, 2023
Figure 54 : Chinese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 55 : Chinese Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 56 : Japanese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 57 : Japanese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 58 : Indian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 59 : Indian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 60 : Australian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 61 : Australian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 62 : Rest of Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 63 : Rest of Asia-Pacific Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 64 : Rest of the World Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 65 : Rest of the World Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 66 : Top 10 Blockbuster Cancer Immunotherapy Products, by Sales Revenue, 2022-2023
Figure 67 : Global Market Shares of Cancer Immunotherapy, by Company, 2023
Figure 68 : Pillars of ESG
Figure 69 : Advantages of ESG for Companies
Figure 70 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 71 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 72 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
Figure 73 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 74 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
Figure 75 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
Figure 76 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
Figure 77 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
Figure 78 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 79 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 80 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
Figure 81 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 82 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
Figure 83 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
Figure 84 : Lilly: Revenue Share, by Business Unit, FY 2023
Figure 85 : Lilly: Revenue Share, by Country/Region, FY 2023
Figure 86 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
Figure 87 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
Figure 88 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 89 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 90 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 91 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Figure 92 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
Figure 93 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
Figure 94 : Sanofi: Revenue Share, by Business Unit, FY 2023
Figure 95 : Sanofi: Revenue Share, by Country/Region, FY 2023
Figure 96 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 97 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023
Figure 98 : Teva Pharmaceutical Industries Ltd.: Market Share, by Business Unit, FY 2023
Figure 99 : Teva Pharmaceutical Industries Ltd.: Market Share, by Country/Region, FY 2023

List of Tables


Summary Table : Global Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 1 : Porter’s Five Forces Analysis: Cancer Immunotherapy Market
Table 2 : Average Price of Immunotherapy
Table 3 : List of Selected Clinical Trial Studies on Immunotherapy, 2025
Table 4 : List of Selected Recent Patents Related to Immunotherapy 2024-2025
Table 5 : Global Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 6 : FDA-Approved Immune Checkpoint Inhibitors 2015–2018
Table 7 : Global Market for Checkpoint Inhibitors in Cancer Immunotherapy, by Region, Through 2029
Table 8 : Global Market for Checkpoint Inhibitors in Cancer Immunotherapy, by Type, Through 2029
Table 9 : Global Market for Monoclonal Antibodies in Cancer Immunotherapy, by Region, Through 2029
Table 10 : Global Market for Adoptive Cell Therapies in Cancer Immunotherapy, by Region, Through 2029
Table 11 : Global Market for Cytokine Therapy in Cancer Immunotherapy, by Region, Through 2029
Table 12 : Global Market for Cancer Vaccines in Cancer Immunotherapy, by Region, Through 2029
Table 13 : Players Investing in Oncolytic Virology, 2024
Table 14 : Global Market for Oncolytic Virus Therapy in Cancer Immunotherapy, by Region, Through 2029
Table 15 : Global Market for Other Immunotherapies in Cancer Immunotherapy, by Region, Through 2029
Table 16 : Global Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 17 : Global Market for Cancer Immunotherapy in Melanoma, by Region, Through 2029
Table 18 : Global Market for Cancer Immunotherapy in Leukemia, by Region, Through 2029
Table 19 : Global Market for Cancer Immunotherapy in Lymphoma, by Region, Through 2029
Table 20 : Global Market for Cancer Immunotherapy in Myeloma, by Region, Through 2029
Table 21 : Global Market for Cancer Immunotherapy in Lung Cancer, by Region, Through 2029
Table 22 : Global Market for Cancer Immunotherapy in Breast Cancer, by Region, Through 2029
Table 23 : Global Market for Cancer Immunotherapy in Colorectal Cancer, by Region, Through 2029
Table 24 : Global Market for Cancer Immunotherapy in Other Cancers, by Region, Through 2029
Table 25 : Global Market for Cancer Immunotherapy, by Region, Through 2029
Table 26 : North American Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 27 : North American Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 28 : North American Market for Cancer Immunotherapy, by Country, Through 2029
Table 29 : U.S. Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 30 : U.S. Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 31 : Canadian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 32 : Canadian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 33 : Mexican Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 34 : Mexican Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 35 : European Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 36 : European Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 37 : European Market for Cancer Immunotherapy, by Country, Through 2029
Table 38 : German Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 39 : German Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 40 : U.K. Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 41 : U.K. Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 42 : French Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 43 : French Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 44 : Italian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 45 : Italian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 46 : Spanish Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 47 : Spanish Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 48 : Rest of European Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 49 : Rest of European Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 50 : Asia-Pacific Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 51 : Asia-Pacific Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 52 : Asia-Pacific Market for Cancer Immunotherapy, by Country, Through 2029
Table 53 : Chinese Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 54 : Chinese Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 55 : Japanese Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 56 : Japanese Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 57 : Indian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 58 : Indian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 59 : Australian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 60 : Australian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 61 : Rest of Asia-Pacific Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 62 : Rest of Asia-Pacific Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 63 : Rest of the World Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 64 : Rest of the World Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 65 : Key Focus Areas in ESG Metrics
Table 66 : ESG Rankings for Leading Companies in Cancer Immunotherapy Market, 2024*
Table 67 : Abbreviations Used in this Report.
Table 68 : Report Sources
Table 69 : AbbVie Inc.: Company Snapshot
Table 70 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 71 : AbbVie Inc.: Product Portfolio
Table 72 : AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 73 : Amgen Inc.: Company Snapshot
Table 74 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 75 : Amgen Inc.: Product Portfolio
Table 76 : Amgen Inc.: News/Key Developments, 2022-2024
Table 77 : AstraZeneca: Company Snapshot
Table 78 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 79 : AstraZeneca: Product Portfolio
Table 80 : AstraZeneca: News/Recent Developments, 2023 and 2024
Table 81 : Bristol-Myers Squibb Co.: Company Snapshot
Table 82 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 83 : Bristol-Myers Squibb Co.: Product Portfolio
Table 84 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
Table 85 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 86 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 87 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 88 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022–2024
Table 89 : Gilead Sciences Inc.: Company Snapshot
Table 90 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
Table 91 : Gilead Sciences Inc.: Product Portfolio
Table 92 : Gilead Sciences Inc.: News/Key Developments, 2023 and 2024
Table 93 : Johnson & Johnson Services Inc.: Company Snapshot
Table 94 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 95 : Johnson & Johnson Services Inc.: Product Portfolio
Table 96 : Johnson & Johnson Services Inc.: News/Key Developments, 2022?2024
Table 97 : Lilly: Company Snapshot
Table 98 : Lilly: Financial Performance, FY 2022 and 2023
Table 99 : Lilly: Product Portfolio
Table 100 : Lilly: News/Key Developments, 2022 and 2023
Table 101 : Merck & Co. Inc.: Company Snapshot
Table 102 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 103 : Merck & Co. Inc.: Product Portfolio
Table 104 : Merck & Co. Inc.: News/Key Developments, 2021–2024
Table 105 : Novartis AG: Company Snapshot
Table 106 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 107 : Novartis AG: Product Portfolio
Table 108 : Novartis AG: News/Key Developments, 2022
Table 109 : Pfizer Inc.: Company Snapshot
Table 110 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 111 : Pfizer Inc.: Product Portfolio
Table 112 : Pfizer Inc.: News/Key Developments, 2023 and 2024
Table 113 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 114 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 115 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 116 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024
Table 117 : Sanofi: Company Snapshot
Table 118 : Sanofi: Financial Performance, FY 2022 and 2023
Table 119 : Sanofi: Product Portfolio
Table 120 : Sanofi: News/Key Developments, 2022–2024
Table 121 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 122 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 123 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 124 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023
Table 125 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 126 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
Table 127 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 128 : Few Emerging Players in Cancer Immunotherapy Market